Free Trial
NASDAQ:ADVM

Adverum Biotechnologies Q1 2024 Earnings Report

Adverum Biotechnologies logo
$2.54 +0.14 (+5.83%)
As of 01:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Adverum Biotechnologies EPS Results

Actual EPS
-$1.50
Consensus EPS
-$1.28
Beat/Miss
Missed by -$0.22
One Year Ago EPS
N/A

Adverum Biotechnologies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adverum Biotechnologies Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, May 9, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Adverum Biotechnologies' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Friday, August 8, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Adverum Biotechnologies Earnings Headlines

Adverum Biotechnologies, Inc. (ADVM) - Yahoo Finance
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Adverum Biotechnologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adverum Biotechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adverum Biotechnologies and other key companies, straight to your email.

About Adverum Biotechnologies

Adverum Biotechnologies (NASDAQ:ADVM) (NASDAQ: ADVM) is a clinical-stage gene therapy company dedicated to developing next-generation treatments for ocular and rare diseases. Headquartered in Redwood City, California, Adverum leverages its proprietary adeno-associated virus (AAV) platform to deliver potentially one-time, durable therapies that address underlying genetic causes. The company’s research focuses on serious conditions with high unmet medical need, including retinal disorders and hemophilia A.

The company’s pipeline includes ADVM-022, an intravitreal AAV-based gene therapy candidate for the prevention and treatment of neovascular age-related macular degeneration (wet AMD), and ADVM-043, which targets diabetic macular edema. In addition, Adverum is advancing ADVM-269, a systemic AAV vector designed to express factor VIII for patients with severe hemophilia A. Each program is designed to reduce or eliminate the need for repeated hospital visits and chronic treatment regimens.

Originally founded as Avalanche Biotechnologies in 2014 and rebranded as Adverum Biotechnologies in 2015, the company completed its initial public offering on the Nasdaq in 2016. Under the leadership of President and CEO Roy Dunbar and Executive Chairman Glenn Rockman, Adverum has grown its scientific capabilities and manufacturing partnerships, including agreements to secure clinical- and commercial-scale AAV vector production.

Adverum operates with a global perspective, conducting clinical trials across North America and Europe and engaging with regulatory authorities to advance its programs. The company’s mission is to bring transformative gene therapies to patients worldwide, harnessing its expertise in vector design and delivery to develop potentially curative treatments for serious disorders.

View Adverum Biotechnologies Profile

More Earnings Resources from MarketBeat